Search Results for: CTLA4

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel AOX1 aldehyde oxidase 1
  • Vitamins B6 activation to pyridoxal phosphate
  • Cyclobenzaprine
  • Eniluracil
  • Xanthinuria
Novel ATP5MC3 ATP synthase membrane subunit c locus 3
  • Formation of ATP by chemiosmotic coupling
  • Cristae formation
Novel BCS1L BCS1 homolog, ubiquinol-cytochrome c reductase complex chaperone
  • Mitochondrial protein import
  • Bjornstad syndrome
  • Mitochondrial respiratory chain deficiencies (MRCD), including: Mitochondrial complex I deficiency (MT-C1D); Complex II deficiency (MT-C2D); Complex III deficiency (MT-C3D); Complex IV deficiency (MT-C4D); Complex V deficiency (MT-ATPSD); Leigh syndrome (LS); Kearns-Sayre Syndrome (KSS); LCHD deficiency (LCHD); Leber Hereditary Optic Neuropathy (LHON); Myoclonic Epilepsy and Ragged-Red Fiber Disease (MERRF); NARP; MELAS; ACAD9 deficiency; HADH deficiency; HIBCH deficiency; GRACILE syndrome
Novel CD28 CD28 molecule
  • PIP3 activates AKT signaling
  • Nef mediated downregulation of CD28 cell surface expression
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
Novel CDC26 cell division cycle 26
  • Inactivation of APC/C via direct inhibition of the APC/C complex
  • APC/C:Cdc20 mediated degradation of Cyclin B
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • APC/C:Cdc20 mediated degradation of Securin
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
  • Regulation of APC/C activators between G1/S and early anaphase
  • APC/C:Cdc20 mediated degradation of mitotic proteins
  • Phosphorylation of the APC/C
  • APC-Cdc20 mediated degradation of Nek2A
  • Separation of Sister Chromatids
  • Senescence-Associated Secretory Phenotype (SASP)
  • CDK-mediated phosphorylation and removal of Cdc6
  • Transcriptional Regulation by VENTX
  • Aberrant regulation of mitotic exit in cancer due to RB1 defects
  • Antigen processing: Ubiquitination & Proteasome degradation
Novel CLK1 CDC like kinase 1
  • Debromohymenialdisine
  • CHGN111
  • ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1H-indole-2-carboxylate
  • Fostamatinib
Novel DCTD dCMP deaminase
  • Interconversion of nucleotide di- and triphosphates
Novel GLP1R glucagon like peptide 1 receptor
  • Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
  • Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
  • G alpha (s) signalling events
  • Glucagon-type ligand receptors
  • ADORA2B mediated anti-inflammatory cytokines production
  • Glucagon
  • Exenatide
  • Liraglutide
  • Albiglutide
  • Dulaglutide
  • Lixisenatide
  • Semaglutide
Novel PLCL1 phospholipase C like 1 (inactive)
  • Quinacrine
Novel SKP1 S-phase kinase associated protein 1
  • Activation of NF-kappaB in B cells
  • Prolactin receptor signaling
  • SCF-beta-TrCP mediated degradation of Emi1
  • Vpu mediated degradation of CD4
  • SCF(Skp2)-mediated degradation of p27/p21
  • Degradation of beta-catenin by the destruction complex
  • Downstream TCR signaling
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Regulation of PLK1 Activity at G2/M Transition
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling
  • FCERI mediated NF-kB activation
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Circadian Clock
  • Dectin-1 mediated noncanonical NF-kB signaling
  • CLEC7A (Dectin-1) signaling
  • Degradation of GLI1 by the proteasome
  • Degradation of GLI2 by the proteasome
  • GLI3 is processed to GLI3R by the proteasome
  • NIK-->noncanonical NF-kB signaling
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Orc1 removal from chromatin
  • Cyclin D associated events in G1
  • FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX2 expression and activity
  • Neddylation
  • Interleukin-1 signaling
  • Iron uptake and transport
  • Negative regulation of NOTCH4 signaling
  • Antigen processing: Ubiquitination & Proteasome degradation
  • 1-naphthaleneacetic acid
  • (2S)-2-(1H-indol-3-yl)hexanoic acid
  • (2S)-2-(1H-indol-3-yl)pentanoic acid
  • (2S)-8-[(tert-butoxycarbonyl)amino]-2-(1H-indol-3-yl)octanoic acid
  • Indoleacetic acid
AP1M1 adaptor related protein complex 1 subunit mu 1
  • Nef mediated downregulation of MHC class I complex cell surface expression
  • MHC class II antigen presentation
  • Lysosome Vesicle Biogenesis
  • Golgi Associated Vesicle Biogenesis
  • Neutrophil degranulation
AP2M1 adaptor related protein complex 2 subunit mu 1
  • Nef mediated downregulation of CD28 cell surface expression
  • Nef Mediated CD4 Down-regulation
  • Retrograde neurotrophin signalling
  • Retrograde neurotrophin signalling
  • Nef Mediated CD8 Down-regulation
  • Gap junction degradation
  • Formation of annular gap junctions
  • MHC class II antigen presentation
  • EPH-ephrin mediated repulsion of cells
  • Recycling pathway of L1
  • Recycling pathway of L1
  • WNT5A-dependent internalization of FZD4
  • WNT5A-dependent internalization of FZD2, FZD5 and ROR2
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • VLDLR internalisation and degradation
  • LDL clearance
  • Potential therapeutics for SARS
CD80 CD80 molecule
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • CTLA4 inhibitory signaling
  • Interleukin-10 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Abatacept
  • Galiximab
  • Belatacept
CD86 CD86 molecule
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • CTLA4 inhibitory signaling
  • Interleukin-10 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Antithymocyte immunoglobulin (rabbit)
  • Abatacept
  • Belatacept
  • Bryostatin 1
CTXN3 cortexin 3
FYN FYN proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • Signaling by ERBB2
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Nef and signal transduction
  • Cell surface interactions at the vascular wall
  • FCGR activation
  • PECAM1 interactions
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • DAP12 signaling
  • EPH-Ephrin signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Nephrin family interactions
  • NCAM signaling for neurite out-growth
  • NCAM signaling for neurite out-growth
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • CTLA4 inhibitory signaling
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • Ephrin signaling
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • CRMPs in Sema3A signaling
  • VEGFA-VEGFR2 Pathway
  • Dectin-2 family
  • CD209 (DC-SIGN) signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Platelet Adhesion to exposed collagen
  • Reelin signalling pathway
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • FLT3 signaling through SRC family kinases
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Dasatinib
  • Triglyme
  • Fostamatinib
JAK2 Janus kinase 2
  • Interleukin-6 signaling
  • Interleukin-6 signaling
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • Prolactin receptor signaling
  • Prolactin receptor signaling
  • Signaling by SCF-KIT
  • Signaling by Leptin
  • RMTs methylate histone arginines
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RAF activation
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • IL-6-type cytokine receptor ligand interactions
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Cyclin D associated events in G1
  • Interferon gamma signaling
  • Regulation of IFNG signaling
  • Regulation of IFNG signaling
  • Interleukin-20 family signaling
  • Interleukin-35 Signalling
  • Signaling by Erythropoietin
  • Interleukin-12 signaling
  • Interleukin-12 signaling
  • Interleukin-23 signaling
  • Interleukin-23 signaling
  • Interleukin-27 signaling
  • Interleukin-27 signaling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Erythropoietin activates STAT5
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Interleukin receptor SHC signaling
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Potential therapeutics for SARS
  • Growth hormone receptor signaling
  • Growth hormone receptor signaling
  • Factors involved in megakaryocyte development and platelet production
  • 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
  • XL019
  • 5-phenyl-1H-indazol-3-amine
  • 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide
  • 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
  • Ruxolitinib
  • Tofacitinib
  • Baricitinib
  • Entrectinib
  • Fostamatinib
  • Fedratinib
  • Zanubrutinib
  • Pralsetinib
  • Polycythemia vera
LCK LCK proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Nef and signal transduction
  • Nef Mediated CD4 Down-regulation
  • Downstream TCR signaling
  • Phosphorylation of CD3 and TCR zeta chains
  • Translocation of ZAP-70 to Immunological synapse
  • Generation of second messenger molecules
  • PECAM1 interactions
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • DAP12 signaling
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • CTLA4 inhibitory signaling
  • PD-1 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Interleukin-2 signaling
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • FLT3 signaling through SRC family kinases
  • Dasatinib
  • AP-22408
  • Staurosporine
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • {4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE
  • 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE
  • N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
  • N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
  • N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine
  • Ponatinib
  • Nintedanib
  • Fostamatinib
  • Zanubrutinib
  • Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
LYN LYN proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Cell surface interactions at the vascular wall
  • FCGR activation
  • PECAM1 interactions
  • Fc epsilon receptor (FCERI) signaling
  • Fc epsilon receptor (FCERI) signaling
  • EPH-Ephrin signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated NF-kB activation
  • CD28 co-stimulation
  • CTLA4 inhibitory signaling
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • EPH-ephrin mediated repulsion of cells
  • Dectin-2 family
  • CD209 (DC-SIGN) signaling
  • CD22 mediated BCR regulation
  • Cyclin D associated events in G1
  • Platelet Adhesion to exposed collagen
  • Signaling by Erythropoietin
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Erythropoietin activates STAT5
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Growth hormone receptor signaling
  • Growth hormone receptor signaling
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Dasatinib
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • Bosutinib
  • Ponatinib
  • Nintedanib
  • Fostamatinib
MALL mal, T cell differentiation protein like

Page 1 out of 2 pages